Equities researchers at StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Get Free Report) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th.
Galectin Therapeutics Trading Up 2.7 %
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. On average, equities research analysts predict that Galectin Therapeutics will post -0.67 earnings per share for the current year.
Hedge Funds Weigh In On Galectin Therapeutics
Several large investors have recently bought and sold shares of GALT. Northern Trust Corp raised its stake in shares of Galectin Therapeutics by 7.6% in the 2nd quarter. Northern Trust Corp now owns 101,964 shares of the company’s stock valued at $147,000 after buying an additional 7,206 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Galectin Therapeutics by 1.5% in the 1st quarter. Geode Capital Management LLC now owns 521,678 shares of the company’s stock valued at $1,096,000 after purchasing an additional 7,863 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Galectin Therapeutics by 21.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 56,184 shares of the company’s stock worth $90,000 after buying an additional 10,000 shares in the last quarter. MML Investors Services LLC lifted its position in shares of Galectin Therapeutics by 28.4% during the 3rd quarter. MML Investors Services LLC now owns 49,777 shares of the company’s stock worth $81,000 after buying an additional 11,000 shares during the period. Finally, State Street Corp boosted its stake in Galectin Therapeutics by 9.4% in the 1st quarter. State Street Corp now owns 173,740 shares of the company’s stock valued at $280,000 after buying an additional 14,981 shares in the last quarter. 12.06% of the stock is currently owned by institutional investors and hedge funds.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Five stocks we like better than Galectin Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in Esports
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.